Drug intelligence / Profile preview

SCT650C

Development stage: Phase 2
Lead developer: Sinocelltech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SCT650C is a humanized monoclonal antibody that targets interleukin 17A (IL-17A). It is being developed by Sinocelltech for the treatment of autoimmune disorders, with a primary focus on diseases such as axial spondyloarthritis and ankylosing spondylitis. The drug acts as an IL-17A inhibitor, blocking the activity of this pro-inflammatory cytokine implicated in several immune-mediated conditions. As of early 2024, SCT650C has completed phase 1 trials in healthy volunteers and is entering phase 2 clinical trials for axial spondyloarthritis[1][2][3][4][5].

Other names: Recombinant anti-IL-17A antibody

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on SCT650C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT650C.

Explore the full profile